Update on Rare Adverse Events from Osteoporosis Therapy and Bisphosphonate Drug Holidays
- 28 April 2021
- journal article
- research article
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 50 (2) , 193-203
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 UpdateEndocrine Practice, 2020
- Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2019
- Fracture Prevention with Zoledronate in Older Women with OsteopeniaNew England Journal of Medicine, 2018
- Hip fracture trends in the United States, 2002 to 2015Osteoporosis International, 2017
- Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2015
- Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996–2012: An Ecological AnalysisJournal of Bone and Mineral Research, 2015
- Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011Journal of Bone and Mineral Research, 2014
- Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trialBone, 2012
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2011
- Effects of Continuing or Stopping Alendronate After 5 Years of TreatmentJAMA, 2006